Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN20566 · 1 trial · 2 indications
Part A
Part A
Part B
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | - |
| Part B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| REGN20566 | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Has a body mass index 27-40 kg/m2, inclusive, at screening visit or prior to randomization 2. Healthy volunteers with obesity Key Exclusion Criteria: 1. A self-reported change of body weight \>5 kg within 90 days of screening visit 2. History of type 1 or 2 diabetes, or...
REGN20566 is an investigational small molecule drug being developed by Regeneron Pharmaceuticals for overweight and obesity. It is in Phase 1 clinical development and has not been approved for any use. It is being studied in adults with overweight or obesity.
REGN20566 is being studied for the treatment of overweight and obesity in adults. Its only listed clinical trial enrolls adults 18 years and older with overweight or obesity. The drug is investigational and has not been approved for any indication.
REGN20566 is being developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. Regeneron is the sponsor of the Phase 1 program evaluating the drug in adults with overweight or obesity.
REGN20566 is in Phase 1 clinical development. It is an investigational drug and is not FDA approved. Its single registered trial is a Phase 1 study that is not yet recruiting, so clinical development is at an early stage.
REGN20566 is being studied in one clinical trial, NCT07947966, titled Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity. The Phase 1 trial is not yet recruiting and is planned to enroll 304 participants in a randomized, double-blind, placebo-controlled design.
The Phase 1 trial NCT07947966 is a randomized, double-blind, placebo-controlled study planned to enroll 304 adults aged 18 years and older with overweight or obesity. It is evaluating safety and drug concentrations of REGN20566 and is currently listed as not yet recruiting.